Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia

Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia

Introduction: Tocilizumab (TCZ) is an interleukin-6 receptor antagonist, which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), which aims to ameliorate the cytokine release syndrome (CRS) induced acute respiratory distress syndrome (ARDS). However, there are no consistent data...

Full description

Bibliographic Details
Main Authors: Miguel Górgolas Hernández-Mora, Alfonso Cabello Úbeda, Laura Prieto-Pérez, Felipe Villar Álvarez, Beatriz Álvarez Álvarez, María Jesús Rodríguez Nieto, Irene Carrillo Acosta, Itziar Fernández Ormaechea, Aws Waleed Mohammed Al-Hayani, Pilar Carballosa, Silvia Calpena Martínez, Farah Ezzine, Marina Castellanos González, Alba Naya, Marta López De Las Heras, Marcel José Rodríguez Guzmán, Ana Cordero Guijarro, Antonio Broncano Lavado, Alicia Macías Valcayo, Marta Martín García, Javier Bécares Martínez, Ricardo Fernández Roblas, Miguel Ángel Piris Pinilla, José Fortes Alen, Olga Sánchez Pernaute, Fredeswinda Romero Bueno, Sarah Heili-Frades, Germán Peces-Barba Romero
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:International Journal of Infectious Diseases
Subjects:
SARS-CoV-2
Covid-19
Tocilizumab
Pneumonia
Treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971220322499

Internet

http://www.sciencedirect.com/science/article/pii/S1201971220322499

Similar Items